Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 11/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565177 | 0.95 | EPHB4 (0.48) | EPHB4KDRABL1EGFRAURKA | |
| SCHEMBL3530692 | 0.86 | KDR (0.50) | EPHB4KDRABL1EGFRAURKA | |
| SCHEMBL3530589 | 0.86 | KDR (0.50) | EPHB4KDRABL1EGFRAURKA | |
| SCHEMBL3563206 | 0.80 | KDR (0.75) | KDRABL1EGFRAURKADYRK3 | |
| SCHEMBL3529631 | 0.80 | KDR (0.59) | EPHB4KDRABL1EGFRAURKA | |
| SCHEMBL4472168 | 0.79 | EPHB4 (0.72) | EPHB4KDRABL1EGFRAURKA | |
| SCHEMBL3530972 | 0.79 | LCK (0.68) | KDRABL1EGFRAURKAROCK2 | |
| SCHEMBL3530966 | 0.79 | LCK (0.68) | KDRABL1EGFRAURKAROCK2 | |
| SCHEMBL3582227 | 0.78 | BRAF (0.64) | KDRABL1EGFRAURKADYRK3 | |
| SCHEMBL27661137 | 0.78 | EPHB4 (0.45) | EPHB4KDRABL1EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | EPHB4 896/4885KDR 494/4885ABL1 1/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | EPHB4 896/4885KDR 494/4885ABL1 1/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | EPHB4 896/4885KDR 494/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.